The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

Sex and gender differences in Parkinson’s disease should be a priority for researchers and clinicians, to ensure appropriate care is provided to patients.

A pheochromocytoma is an intra-adrenal paraganglioma ... procedures Localization studies should only follow reasonable clinical and/or biochemical evidence of a tumor Although CT and MRI have ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic ... Crohn's disease have shared with us how truly disruptive ...

Creating two distinct classifications of “clinical obesity” and “pre-clinical obesity” would provide more accurate diagnosis and more personalised treatment, it argued.

You may have heard that frequent snoring is a sign of sleep apnea. It's true that snoring is one of the most common symptoms. But not everyone who has sleep apnea snores. And of course ...

bnHealth Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Science, Medical University of Silesia, Katowice, Poland boSchool of Public Health, Tongji Medical ...

This Commission sought to define clinical obesity as a condition of illness that, akin to the notion of chronic disease in other medical specialties, directly results from the effect of excess ...